158 related articles for article (PubMed ID: 10608481)
21. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
[TBL] [Abstract][Full Text] [Related]
22. The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine.
Jokinen MJ; Ahonen J; Neuvonen PJ; Olkkola KT
Anesth Analg; 2000 Nov; 91(5):1207-12. PubMed ID: 11049910
[TBL] [Abstract][Full Text] [Related]
23. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
24. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
25. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
Yamazaki H; Shimada T
Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
[TBL] [Abstract][Full Text] [Related]
26. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
27. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
28. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro.
Rasmussen BB; Nielsen TL; Brøsen K
Pharmacol Toxicol; 1998 Dec; 83(6):240-5. PubMed ID: 9868741
[TBL] [Abstract][Full Text] [Related]
29. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
30. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
31. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
Gibbs MA; Thummel KE; Shen DD; Kunze KL
Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
[TBL] [Abstract][Full Text] [Related]
33. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
34. A study of the in vitro interaction between lidocaine and premedications using human liver microsomes.
Nagashima A; Tanaka E; Inomata S; Honda K; Misawa S
J Clin Pharm Ther; 2005 Apr; 30(2):185-8. PubMed ID: 15811173
[TBL] [Abstract][Full Text] [Related]
35. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Nakajima M; Nakamura S; Tokudome S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Dec; 27(12):1381-91. PubMed ID: 10570018
[TBL] [Abstract][Full Text] [Related]
36. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Pan L; Belpaire FM
Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
[TBL] [Abstract][Full Text] [Related]
37. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
Rasmussen BB; Nielsen TL; Brøsen K
Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
[TBL] [Abstract][Full Text] [Related]
38. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
39. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
Sutton D; Butler AM; Nadin L; Murray M
J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
[TBL] [Abstract][Full Text] [Related]
40. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
